Literature DB >> 23462602

Sweat testing to monitor drug exposure.

Cristiana Gambelunghe1, Riccardo Rossi, Kyriaki Aroni, Mauro Bacci, Andrea Lazzarini, Nadia De Giovanni, Paola Carletti, Nadia Fucci.   

Abstract

It may be advantageous to use sweat, rather than blood or urine, to monitor individuals' drug exposure for the purposes of drug treatment programs, employment initiatives, and forensic investigations. Forty-eight patients receiving methadone at the Public Service for the Treatment of Drug Dependence of Perugia (Italy) were monitored for 14 days by the analysis of methadone and cocaine present in two sweat patches, each worn for 7 days. The results were compared to those from the analysis of urine samples collected at the beginning of the study and after 7 days, as well as those from the analysis of hair collected on the fourteenth day. Sweat patch analysis was positive for methadone and its metabolite EDDP in 100% of patients. Some individuals were positive for cocaine in urine, sweat, and hair while others were positive for cocaine in only one of those samples. Results suggest analysis of a sweat patch indicates an individual's drug use or drug washout for the previous week, and provides an alternative to blood or urine analyses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23462602

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  3 in total

Review 1.  Mechanisms of change associated with technology-based interventions for substance use.

Authors:  Jesse Dallery; Brantley Jarvis; Lisa Marsch; Haiyi Xie
Journal:  Drug Alcohol Depend       Date:  2015-03-12       Impact factor: 4.492

2.  A New Frontier: Integrating Behavioral and Digital Technology to Promote Health Behavior.

Authors:  Jesse Dallery; Allison Kurti; Philip Erb
Journal:  Behav Anal       Date:  2014-08-23

3.  Evidence for the transfer of methadone and EDDP by sweat to children's hair.

Authors:  Hilke Andresen-Streichert; Justus Beike; Katharina Feld; Patrick Dahm; Tobias Kieliba; Axel Klee; Markus A Rothschild
Journal:  Int J Legal Med       Date:  2021-04-05       Impact factor: 2.686

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.